(PharmaNewsWire.Com, December 06, 2018 ) According to the new market research report “Digital Therapeutics Market by Application (Prevention (Prediabetes, Obesity), Care (Diabetes, CVD, CNS, CRD, Smoking Cessation, Musculoskeletal)), Sales Channel (B2C (Patient, Caregiver), B2B (Provider, Payer, Employer, Pharma)) - Global Forecast to 2021", published by MarketsandMarkets™, The global digital therapeutics market is expected to reach USD 457.9 Million by 2021 from USD 110 Million in 2016, growing at a CAGR of 27.7% from 2016 to 2021.
On the basis of application, the digital therapeutics market is segmented into preventive and treatment/care applications. The preventive applications segment is further categorized into prediabetes and obesity. The treatment/care applications segment is further categorized into cardiovascular diseases, smoking cessation, medication adherence, diabetes, CNS diseases, respiratory diseases, musculoskeletal disorders, and other applications (including wellness; post-operative care; pregnancy and parenting; and personal goals and habit platforms). The preventive applications segment is expected to grow at the highest CAGR during the forecast period. Its high growth can be attributed to government initiatives to increase the focus on preventive healthcare and a rising consensus among policy makers, providers, and patients on the superior effectiveness of preventive measures and behavioral and lifestyle changes as compared to pills or surgical procedures.
Browse and in-depth TOC on “Digital Therapeutics Market” 148 - Tables
The key strategies followed by most companies in the digital therapeutics market are agreements, collaborations, and partnerships; investments; and new product launches. Among all growth strategies adopted by market players, agreements, collaborations, and partnerships accounted for the largest share of the overall growth strategies mapped from 2013 to 2016. Some leading players adopting these strategies include Proteus Digital Health, Inc. (U.S.), Omada Health Inc. (U.S.), WellDoc Inc. (U.S.), Livongo Health (U.S.), Noom Inc. (U.S.), Ginger.io Inc. (U.S.), Propeller Health (U.S.), 2Morrow Inc. (U.S.), and Mango Health Inc. (U.S.).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
